当前位置: X-MOL 学术Drug Resist. Updat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nanomedicine to target multidrug resistant tumors.
Drug Resistance Updates ( IF 24.3 ) Pub Date : 2020-05-25 , DOI: 10.1016/j.drup.2020.100704
Elise Lepeltier 1 , Patricia Rijo 2 , Flavio Rizzolio 3 , Rachela Popovtzer 4 , Vilma Petrikaite 5 , Yehuda G Assaraf 6 , Catherine Passirani 1
Affiliation  

Nanomedicine employs nanotechnologies to develop innovative applications, and more specifically nano-objects in the field of human health, through exploitation of the physical, chemical and biological properties of materials at the nanoscale. The use of nanovehicles capable of transporting and releasing the active therapeutic payload into target cells, particularly in the case of cancer or inflammatory diseases, can also enhance diagnosis. Therefore, nanomedicines improve the benefit/risk ratio of drugs by increasing their bioavailability, selectivity, and efficacy in the target tissue, while reducing the necessary doses and hence diminishing untoward toxicity to healthy tissues. Overcoming multidrug resistance (MDR) to antitumor agents is a central goal of cancer research and therapeutics, making it possible to treat these diseases more accurately and effectively. The adaptability of nanomedicines e.g. modulation of their components, surface functionalization, encapsulation of various active therapeutics as well as the possibility of combining several treatments using a single nanoparticle platform, are characteristics which are perfectly poised to address classical chemoresistance, a major obstacle towards curative cancer therapy. In this review, we discuss an assortment of nanomedicines along with those that should be developed in order to surmount cancer MDR; these include exosomes, natural compounds, lipid nanocapsules, prodrug self-assemblies, and gold nanoparticles.



中文翻译:

纳米药物靶向多重耐药性肿瘤。

纳米医学通过开发纳米级材料的物理,化学和生物学特性,利用纳米技术来开发创新应用,尤其是人类健康领域的纳米对象。能够将活性治疗有效载荷运输和释放到靶细胞中的纳米载体的使用,特别是在癌症或炎性疾病的情况下,也可以增强诊断。因此,纳米药物通过增加药物在靶组织中的生物利用度,选择性和功效,同时减少必需的剂量,从而减少了对健康组织的不良毒性,从而提高了药物的获益/风险比。克服抗肿瘤药的多药耐药性是癌症研究和治疗的主要目标,使更准确有效地治疗这些疾病成为可能。纳米药物的适应性,例如其成分的调节,表面功能化,各种活性疗法的封装以及使用单个纳米颗粒平台组合多种疗法的可能性,这些特征完全可以解决经典的化学耐药性,这是治愈癌症的主要障碍治疗。在这篇综述中,我们讨论了各种各样的纳米药物以及应该克服的纳米药物;这些包括外泌体,天然化合物,脂质纳米胶囊,前药自组装体和金纳米颗粒。各种活性疗法的封装以及使用单个纳米粒子平台组合多种疗法的可能性,这些特征完全可以解决经典的化学抗药性,这是治愈性癌症治疗的主要障碍。在这篇综述中,我们讨论了各种各样的纳米药物以及应该克服的纳米药物;这些包括外泌体,天然化合物,脂质纳米胶囊,前药自组装体和金纳米颗粒。各种活性疗法的封装以及使用单个纳米粒子平台组合多种疗法的可能性,这些特征完全可以解决经典的化学抗药性,这是治愈性癌症治疗的主要障碍。在这篇综述中,我们讨论了各种各样的纳米药物以及应该克服的纳米药物;这些包括外泌体,天然化合物,脂质纳米胶囊,前药自组装体和金纳米颗粒。我们讨论了各种各样的纳米药物以及应该克服的纳米药物,以克服癌症的多药耐药性。这些包括外泌体,天然化合物,脂质纳米胶囊,前药自组装体和金纳米颗粒。我们讨论了各种各样的纳米药物以及应该克服的纳米药物,以克服癌症的多药耐药性。这些包括外泌体,天然化合物,脂质纳米胶囊,前药自组装体和金纳米颗粒。

更新日期:2020-05-25
down
wechat
bug